Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666575 | 1.00 | FFAR4 (0.40) | FFAR4FFAR1PPARGPPARDPPARA | |
| SCHEMBL1946326 | 0.89 | FFAR1 (0.42) | FFAR4FFAR1PPARGPPARDPPARA | |
| SCHEMBL1946329 | 0.89 | FFAR1 (0.42) | FFAR4FFAR1PPARGPPARDPPARA | |
| SCHEMBL3532600 | 0.80 | PTPN1 (0.39) | FFAR4FFAR1 | |
| SCHEMBL3532597 | 0.80 | PTPN1 (0.39) | FFAR4FFAR1 | |
| SCHEMBL3666552 | 0.79 | MCHR1 (0.39) | FFAR4FFAR1 | |
| SCHEMBL3666550 | 0.79 | MCHR1 (0.39) | FFAR4FFAR1 | |
| SCHEMBL1943744 | 0.78 | CYP4F2 (0.41) | FFAR4FFAR1HSD17B10 | |
| SCHEMBL1943746 | 0.78 | CYP4F2 (0.41) | FFAR4FFAR1HSD17B10 | |
| SCHEMBL3530435 | 0.78 | CYP11B1 (0.36) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046395-A1 | PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2238107-A1 | PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092580-A1 | PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046395-A1 | PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE | FDPS, DHPS, UGT1A6 | FFAR4 648/4885FFAR1 1072/4885PPARG 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.